^
Association details:
| Biomarker: | ROS1 rearrangement |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
Excerpt:
...- Histologically or cytologically confirmed diagnosis of stage IV or incurable non-squamous non-small cell lung cancer with a documented ROS1 rearrangement (cohort 1) or MET-activating mutation (exon 14) (cohort 2) or MET-amplification (cohort 3) tested in either plasma or tissue, as applicable...
Trial ID:
Source:
Title:
Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer
Excerpt:
...Documented evidence of an ALK rearrangement (by FISH, IHC, or NGS), ROS1 rearrangement (by FISH or NGS), or MET oncogene as defined by MET exon 14 skipping (NGS), MET Y1003X mutation or MET gene fusion (NGS) in NSCLC tumor specimen by a CLIA-approved laboratory....
Trial ID:
Less C2 evidence
Source:
Title:
Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes
Published date:
03/17/2022
Excerpt:
... two patients who had ROS1 IGRs demonstrated a clinical benefit after 13 and 19 months on crizotinib, respectively.
DOI:
https://doi.org/10.1016/j.esmoop.2022.100405
Source:
Title:
Experience on the diagnosis and treatment of multiple active primary cancers in our Institution
Published date:
05/19/2021
Excerpt:
Six MAPC patients including 1 ROS-1 rearranged lung cancer, 4 EGFR mutant lung cancer, and 2 HER2 positive breast cancer were treated with corresponding targeted agents (crizotinib, gefitinib and lapatinib). Four responses (1 CR and 3 PR) and 2 stable disease (PFS 33+ and 132 months) were observed. Three of the four responders had a PFS of 1+, 29+ and 27 months...
DOI:
10.1200/JCO.2021.39.15_suppl.e15097
